A global pharmacovigilance database analysis linked isotretinoin monotherapy to rhabdomyolysis reports. The disproportionality analysis identified 130 spontaneous reports and a statistically significant reporting association compared with what would be expected by background patterns in VigiBase. While spontaneous-report analyses cannot establish causality, the signal can change how clinicians screen for risk factors and monitor patients, especially where concomitant medications or comorbidities might amplify muscle injury risk. For regulators and safety teams, the key next step is to triangulate the finding with clinical case details and any emerging epidemiologic evidence.